GLP-1R agonists ameliorate both diabetes and obesity, decrease cardiovascular events, stroke and nephropathy in clinical trials8,9 and ameliorate dementia and stroke in preclinical studies51. The gene discussed is GLP1R; the disease is Nephropathy.